German Government announced its decision to change rules to induce drug-makers to charge less for their products last month.
The step was successfully initiated from June 1 & resulted in price reduction announcements by chief German generic companies including Stada & Novartiz. The reductions were to the true of over 20%.
The overall impact may result into a reduction in margins for all generic players and this would affect Indian pharma companies operating in the $26.7 billion German market. Dr. Reddy’s has the maximum exposure in the German market of all the Indian companies, with the company’s recent acquisition of Betapharm, a leading German Generic Player.
Popularity: 1% [?]
No Comment
Random Post
Leave Your Comments Below